Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

Small cell lung cancer (SCLC) often responds well to initial treatment before later relapsing. Researchers are continuing to investigate new treatments, such as targeted therapy and immunotherapy ...

Small cell lung cancer (SCLC) is among the most aggressive types of lung cancer, with a five-year survival rate of just five percent. Although it often responds well to chemotherapy at first, that ...

Combining immunotherapy with chemotherapy may improve survival in extensive-stage small cell lung cancer without increasing treatment-related toxicity. The study showed a median overall survival of 14 ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

LEMS is an autoimmune disorder linked to SCLC, causing muscle weakness and autonomic dysfunction due to presynaptic calcium channel antibodies. Differentiation from myasthenia gravis involves ...

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...